Key Takeaways Shares of Inari Medical surged Monday afternoon and again Tuesday morning as reports of an imminent acquisition by Stryker turned into reality.Stryker will acquire Inari in an all-cash deal for $80 per share,

Medical device maker Stryker said it has reached a deal to acquire Inari Medical for $80 per share in cash, representing an approximate value of $4.9 billion.

Stryker has agreed to acquire medical technology maker Inari Medical in a deal worth $4.9 billion, the companies said Monday.The medical device maker plans to buy all of Inari’s common stock for $80 a share,

Stryker has entered a definitive agreement to acquire complete issued and outstanding shares of Inari Medical’s common stock for $80 per share in cash, which equates to a total equity value of nearly $4.9bn. Inari is poised to enhance Stryker's footprint in the peripheral vascular sector, particularly in the venous thromboembolism (VTE) market.

Stryker said it has a definitive agreement to purchase Inari Medical for $80 per share, a big premium that values the deal at $4.9 billion.

Inari Medical's stock surged 6% amid reports of advanced acquisition talks with Stryker, potentially closing a deal this week.

Stryker said its planned acquisition of Inari Medical would strengthen its position in the peripheral vascular market.

Fintel reports that on January 7, 2025, William Blair downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Outperform to Market Perform. Analyst Price Forecast Suggests 14.20% Downside As of December 23,